Profiling of Target Molecules for Immunotherapy in Mesenchymal Tumors

Abstract

The use of anti-human signal molecules monoclonal antibod-ies (mAbs) for malignant tumors therapy has achieved consid-erable success in recent years. Antibody drug conjugates are powerful new clinical treatment options for lymphomas and solid tumors, and immunomodulatory antibodies have also re-cently achieved remarkable clinical success. The development of therapeutic antibodies requires a deep understanding of ma-lignant tumor serology, protein-engineering techniques, mech-anisms of action and resistance, and the interplay between the immune system and tumorigenesis. This review outlines the fundamental strategies, which are required to establish anti-body therapies for patients with mesenchymal tumors through iterative approaches to target and antibody selection, extend-ing from preclinical studies to human trials.